For women facing diminished ovarian reserve, the most devastating phrase in clinical practice is “your ovarian age is advanced.” As AMH levels drop and egg counts dwindle, the desperation for a “miracle” therapy often becomes overwhelming. Enter Platelet-Rich Plasma (PRP) ovarian injection—a treatment dubbed “ovarian rejuvenation” that promised to reverse the biological clock of the ovaries.
For years, clinics offered this procedure at a high cost, and online forums were filled with anecdotal success stories: “My AMH went up,” or “I finally retrieved more eggs.” It became a beacon of hope, leading many to invest thousands of dollars into a procedure that was marketed as a regenerative breakthrough.
The Verdict of Rigorous Science However, the scientific enthusiasm has met a sobering reality. At the 2026 Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in Paris, the results of a high-quality randomized controlled trial (RCT)—the gold standard of clinical evidence—were presented. The results were clear: there was no statistically significant difference in ovarian responsiveness, oocyte yield, embryo numbers, or embryo quality between the women who received PRP therapy and those who did not.
This study does not simply conclude that “PRP is ineffective.” It forces a much harder question: “On what basis have we been placing our trust?”
The Gap Between Anecdote and Evidence PRP was never a settled clinical science. Most early reports suggesting success were small-scale, lacked control groups, or relied on the natural variability of ovarian function rather than the treatment itself. Yet, the fertility market, driven by the patient’s urgent need for results, accelerated ahead of scientific validation. In the fertility world, patient testimonials often travel faster than peer-reviewed papers, and anecdotal “success” can often sound more persuasive than rigorous scientific skepticism.
The Ethics of Selling Hope The fertility industry faces an uncomfortable truth here: desperation cannot be a business model. Patients struggling with infertility are vulnerable, often lacking the time to wait for longitudinal studies. When an unproven therapy is marketed as a “rejuvenation” procedure, it exploits this vulnerability.
“Ovarian rejuvenation” and “ovarian regeneration” are enticing terms, but at this stage, they belong in the realm of aspiration, not medical fact. While further research into specific patient subsets continues, the current scientific consensus is that we cannot claim to be “making eggs younger.”
Conclusion: Reproductive Medicine as a History of Validation The history of reproductive medicine is not a history of miracles; it is a history of validation. Therapies that endure the test of rigorous evidence become the standard of care; those that fail to prove their efficacy quietly vanish.
The message from ESHRE 2026 is simple: while patients rightly seek to hear “there is hope,” the medical community must first be able to answer “is there evidence?” Until proven otherwise, PRP therapy should be viewed as an experimental approach rather than a standard treatment. We must prioritize honesty over marketing, ensuring that even in the face of infertility, our decisions remain grounded in objective science rather than the promise of a miracle that has yet to be verified.
Sources: ESHRE 2026 Annual Meeting presentations; randomized controlled trials (RCTs) regarding PRP in ovarian insufficiency; expert consensus on regenerative fertility therapies.
Disclaimer: This report is for informational purposes. Clinical procedures should be discussed with a reproductive specialist who adheres to evidence-based medical standards.